- Home
- ATCH vs BTAI Comparison
ATCH vs BTAI Comparison
Compare ATCH & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ATCH | BTAI |
|---|---|---|
| Founded | 2022 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.9M | 35.6M |
| IPO Year | 2024 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ATCH | BTAI |
|---|---|---|
| Price | $0.18 | $1.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $23.25 |
| AVG Volume (30 Days) | ★ 1.5M | 1.2M |
| Earning Date | 05-15-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $173.53 |
| P/E Ratio | $3.24 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.14 | $1.17 |
| 52 Week High | $1.92 | $8.08 |
Technical Indicators
Market Signals| Indicator | ATCH | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 28.23 | 32.21 |
| Support Level | $0.17 | N/A |
| Resistance Level | $0.24 | $1.77 |
| Average True Range (ATR) | 0.01 | 0.12 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 2.21 | 0.00 |
Price Performance
Historical ComparisonAbout ATCH AtlasClear Holdings Inc.
AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.